Breaking News

Lee Reports Net Loss

November 22, 2005

Health and beauty aid company Lee Pharmaceuticals issued results for the fiscal year ended Sept. 30, 2004.
For the fiscal year, net revenues were $8.5 million, a 3% decline compared to the previous year. Offsetting the decreases somewhat were increases in the private label category, as well as added sales of a newly-acquired brand. Lee also reported increases in several over-the-counter items. Overall, sales fell about 3%. This decline was attributed primarily to lower sales volume in the Lee Lip-Ex lip balms and other personal care products. Lee Pharmaceuticals executives said these declines are to be expected from older brands that are not currently supported by advertising or promotion.
blog comments powered by Disqus
  • Cosmetic Chemists Head to Orlando Next Month

    Cosmetic Chemists Head to Orlando Next Month

    September 26, 2016
    Organizing Chair Guy Padulo explains why you should attend the IFSCC Congress.

  • Restoring Rembrandt

    Restoring Rembrandt

    Christine Esposito, Associate Editor||September 26, 2016
    Ranir LLC has acquired Rembrandt, an iconic name in teeth whitening, and plans to make it a staple in the value segment.

  • Active Agents

    Active Agents

    September 19, 2016
    On the surface, surfactants may seem staid, but the market, and the supplier activity driving it, is bubbling.

  • Back to School

    Back to School

    Tom Branna, Editorial Director||September 1, 2016
    It may be September, but class was in session this summer during the Private Label Manufacturers Association’s Executive Educ

  • What

    What's In Your Formula?

    Christine Esposito, Associate Editor||September 1, 2016
    A look at the ingredients beauty brands are using to fuel their formulations and capture consumers’ attention.

  • A Sweet-Smelling Sanctuary

    A Sweet-Smelling Sanctuary

    Melissa Meisel, Associate Editor||September 1, 2016
    Home fragrance is enhanced by aromatic developments in delivery and components.